Format

Send to

Choose Destination
Pediatr Res. 2012 Apr;71(4 Pt 2):459-63. doi: 10.1038/pr.2011.53. Epub 2012 Jan 25.

Human cord blood for the hypoxic-ischemic neonate.

Author information

1
Department of Neurology, Georgia Health Sciences University, Augusta, Georgia, jcarroll@georgiahealth.edu

Abstract

Autologous umbilical cord blood (UCB) is a possible, but unproven, treatment for acute neonatal brain damage. Mesenchymal stem cells (MSCs), which are present in UCB, are likely to be the treating cell type. UCB is effective in the treatment of neonatal rodent hypoxic-ischemic injury (HI) and other types of brain injury when the cells are delivered acutely. Other types of adult stem cells are similarly effective. However, several negative studies have been reported. The most likely mechanisms of action are participation in blood vessel regeneration, improvement of survival of intrinsic cells, perhaps via neurotrophic factors, or suppression of the release of inflammatory cells from the spleen. In the latter case, the splenic inflammatory cells released at the time of injury are thought to have an adverse effect on brain injury. The timing of the administration of the UCB with respect to the time of the injury appears to be the most important issue: the earlier the better. The risks of autologous administration of UCB are minimal. Current clinical trials with UCB are in progress, but there are no peer-reviewed reports as yet. A multicenter trial with specific inclusion criteria is needed.

PMID:
22278181
PMCID:
PMC3640287
DOI:
10.1038/pr.2011.53
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center